Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-06-14-Speech-4-330-812"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20120614.22.4-330-812"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"−
I voted in favour of this resolution because tests conducted by the French authorities on the physical integrity of a sample of silicone breast implants from the French company PIP indicated weaknesses in PIP shells not found in other commercially available implants and this poses a significant danger to women’s health. There is still a lack of both clinical and epidemiological data on the potential risks of PIP breast implants. For third-generation implants there is a rate of rupture within ten years of implantation of 10-15%. The desire to provide swift access to new medical devices for patients must never take precedence over the need to ensure patient safety. Cooperation therefore needs to be strengthened within the existing legal framework, in particular in the fields of market surveillance and inspection, and controls need to be tightened, in order to provide a better guarantee of safety for patients."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples